Navigation Links
Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
Date:5/23/2013

ts include, but are not limited to, Omeros' expectations that it will advance OMS824 into Phase 2 clinical programs for Huntington's disease and schizophrenia this year; regarding the potential therapeutic benefits of OMS824; and that it may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
2. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
3. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
4. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
5. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
6. Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
7. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
8. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
9. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
10. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
11. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... BEIJING , Oct. 30, 2014 China ... "Company"), a leading fully integrated plasma-based biopharmaceutical company in ... Company plans to release third quarter 2014 financial results ... The Company,s management will hold a ... November 6, 2014, which is 8:30 p.m., Beijing Time ...
(Date:10/30/2014)...  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced an upcoming presentation highlighting its ... The presentation, titled, "Drug Conjugates Bind Covalently to ... Sant P. Chawla , M.D., F.R.A.C.P., Director ... of the Company,s ongoing global, pivotal Phase 3 ...
(Date:10/30/2014)... 2014 Extensiv hydrolysierte ... von Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ist ... und Kleinkindern. Der bisher übliche Umgang mit ... Babys bzw. deren stillenden Mütter Milchproteine zu ... bei einer beträchtlichen Anzahl von Kindern der ...
Breaking Medicine Technology:China Biologic to Report Third Quarter 2014 Financial Results 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3
... -- Concord Medical Services Holdings Limited ("Concord Medical" ... of the largest network of radiotherapy and diagnostic imaging centers ... the third quarter ended September 30, 2011. ... were RMB124.7 million ($19.6 million)(A) in the third quarter 2011, ...
... -- Nephros, Inc. (OTC Bulletin Board: NEPH ) ... 30, 2011. Recent Highlights ... to be exercised; Received initial review questions from FDA ... Financial Performance for the Third ...
Cached Medicine Technology:Concord Medical Reports Third Quarter 2011 Financial Results 2Concord Medical Reports Third Quarter 2011 Financial Results 3Concord Medical Reports Third Quarter 2011 Financial Results 4Concord Medical Reports Third Quarter 2011 Financial Results 5Concord Medical Reports Third Quarter 2011 Financial Results 6Concord Medical Reports Third Quarter 2011 Financial Results 7Concord Medical Reports Third Quarter 2011 Financial Results 8Concord Medical Reports Third Quarter 2011 Financial Results 9Concord Medical Reports Third Quarter 2011 Financial Results 10Concord Medical Reports Third Quarter 2011 Financial Results 11Concord Medical Reports Third Quarter 2011 Financial Results 12Concord Medical Reports Third Quarter 2011 Financial Results 13Concord Medical Reports Third Quarter 2011 Financial Results 14Concord Medical Reports Third Quarter 2011 Financial Results 15Nephros Reports Third Quarter 2011 Financial Results 2Nephros Reports Third Quarter 2011 Financial Results 3Nephros Reports Third Quarter 2011 Financial Results 4Nephros Reports Third Quarter 2011 Financial Results 5
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... been identified that appear linked to autism spectrum disorders, ... are on their way to discovering up to 1,000 ... Autism spectrum disorders include a range of developmental disabilities ... An estimated one in 68 U.S. children has an ...
(Date:10/30/2014)... 30, 2014 Horse Sense & ... riding to special needs individuals in the Jacksonville area, ... November 15 from 10-2:00 p.m. at Bailey's Farm (2202 ... to the public and is designed to raise awareness ... to the HSS Round-Up is free. Ticket purchases will ...
(Date:10/30/2014)... 30, 2014 The human brain is ... vigorously exercised to help maintain better mental health, according ... ‘Dementia Express: Lose Your Memory in 100 Ways’ for ... and sometimes conflicting attitudes to help keep the reader ... a reader must decipher the hidden logic within. , ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- When it comes to heart ... men to delay care when they have symptoms that spell ... to the hospital with a more severe or advanced stage ... study author Catherine Kreatsoulas, a Fulbright Scholar and research fellow ... news release from the Heart and Stroke Foundation of Canada. ...
(Date:10/30/2014)... Many U.S. colleges have indoor tanning salons on ... risk for skin cancer, researchers report. Tanning ... so colleges should adopt tanning-free policies, to help ... health efforts are needed to raise university administration ... indoor tanning poses to young adults in order ...
Breaking Medicine News(10 mins):Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2
... Alcohol Support Team Board of Directors and Commits all ... Corporate Charity Work to Benefit FASTeam, ... a year, more than Spina Bifida, Down Syndrome and Muscular,Dystrophy ... an,increase in efforts to promote prevention of prenatal alcohol exposure ...
... LAKE FOREST, Ill., July 7 Hospira, Inc.,(NYSE: ... today announced that it will host a conference call ... 2008, at 8 a.m. Central,time., The company will ... stock market open and the conference call., A ...
... 100%, ARLINGTON HEIGHTS, Ill., July 7 ... are satisfied with,their decision, have low complication rates ... study in July,s Plastic and Reconstructive Surgery(R), the,official ... Surgeons,(ASPS). In addition, breast reconstruction after preventive mastectomy ...
... 2 should be tested for high cholesterol, group says , , ... to the impact of the childhood obesity epidemic in the ... kids as young as 8 years old be given cholesterol-lowering ... , The American Academy of Pediatrics also recommends that children ...
... AIDS Fundraising Event Goes GREEN with Online ... Communications, Recycling and Awareness, SAN FRANCISCO, July ... Francisco announced today key initiatives to ,Green, the,HIV fundraising event ... introduction of Green Walkers, composting, and,enhanced recycling., "With the ...
... MEETING, Pa., July 7 /Xinhua-PRNewswire/ -- BMP ... ,Company,) today,announced that it received the New ... enterprise with foreign investment in the People,s,Republic ... Industry and,Commerce (SHAIC). With receipt of this ...
Cached Medicine News:Health News:K Squared Sponsors F.A.S.T. Ride 150-mile Motorcycle Tour August 17 2Health News:98% of Elective Mastectomy Patients Would Have Reconstruction Again, Says ASPS Study 2Health News:Pediatricians Recommend Cholesterol Drugs for Some Kids 2Health News:Pediatricians Recommend Cholesterol Drugs for Some Kids 3Health News:AIDS Walk San Francisco Takes Big Green Step Forward 2Health News:AIDS Walk San Francisco Takes Big Green Step Forward 3Health News:BMP Sunstone Completes Acquisition of Shanghai Rongheng Pharmaceutical Co., Ltd 2
Pediatric model. Blades: 10 mm. Solid blades with locking mechanism. Dull finish....
Solid 16 mm blades. Self-locking mechanism. Dull finish....
Fenestrated 16 mm blades. Self-locking mechanism. Dull finish....
... The Kawesch-Lancaster Lasik speculum ... one curved to provide clearance ... solid blades retract the lids ... path for the microkeratome. The ...
Medicine Products: